weekly-digest

Landmark DCIS trial, CRC microbiome & AML combos

Dan Manning

Dan Manning

— 42 min read
Share

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance for DCIS produces invasive breast cancer survival equivalent to immediate surgery — a finding that could spare thousands of women surgery each year. In lung cancer, a PET/CT-guided approach identified NSCLC patients who can safely skip radiotherapy after responding to immunotherapy, while 10-year breast cancer radiotherapy data confirmed that tailored nodal approaches hold recurrence below 3%.

The second theme is resistance — and emerging clarity about how to break it. In AML, leukemic stem cells were shown to compensate for PI3K inhibition by upregulating EZH1/2, a bypass route closeable with combination therapy. In BRCA-mutant breast cancer, two distinct PARP inhibitor resistance mechanisms were mapped from patient samples — one reversible with ATR and STAT3 inhibitors. And a new study finally explained why BET inhibitors keep failing in clinical trials: BRD2 and BRD4 have non-overlapping functions that pan-BET inhibitors inadvertently disrupt. Together these findings suggest that targeted therapy’s next chapter is less about finding new targets and more about anticipating how tumors escape them.

breast-cancer

De-escalation dominated breast cancer this week. Landmark randomized data confirmed active surveillance for DCIS produces survival equivalent to immediate surgery, and analysis of 4,400+ patients found women under 50 with small, low-grade tumors have the same low nodal metastasis rates as older patients — meaning age alone does not justify axillary surgery. Ten-year radiotherapy data confirmed sub-3% locoregional recurrence with tailored nodal approaches, and modern radiation delivery appears to have substantially reduced the cardiac toxicity that plagued left-sided breast cancer treatment a generation ago. Mechanistically, new work mapped two distinct PARP inhibitor resistance mechanisms in BRCA-mutant disease and identified MMP14 as a universal invasion enzyme active regardless of how cancer cells move.

colorectal-cancer

Two converging stories dominated colorectal cancer this week: the microbiome and disparities. A landmark 9,000-patient analysis confirmed that colorectal tumors harbor a microbial fingerprint unique among all cancer types — no other cancer type showed a consistent microbial signature — and new long-read sequencing technology can now resolve species within Fusobacterium precisely enough to implicate F. animalis specifically. On the disparities front, poverty was confirmed as a major driver of CRC mortality, and globally, colorectal cancer incidence is rising in wealthier nations even as mortality falls. Mechanistically, autophagy protein p62 was shown to play a dual role — suppressing inflammation early but driving tumorigenesis when it accumulates — adding nuance to what had been viewed as a simple tumor suppressor story.

other-cancer

A breakthrough in understanding why BET inhibitors keep failing in clinical trials was one of this section's most consequential findings: BRD2 and BRD4 have non-overlapping functions, and pan-BET inhibitors disrupt both simultaneously in counterproductive ways — the field now needs selective BRD4 inhibitors. Alongside this, preclinical evidence that zeaxanthin, a common eye-health supplement, strengthens T cells and enhances immunotherapy effectiveness sparked interest in dietary modulation of cancer immunity. Expert consensus moved the obesity-oncology interface toward clinical practice, with calls to integrate GLP-1 drugs and bariatric surgery into standard cancer survivorship care. A large real-world study confirmed HPV vaccine protection in males, and AI tools continued advancing into cancer diagnostics and mutation querying.

blood-cancer

AML dominated hematology this week with several mechanistically important findings. A 30-year Japanese dataset revealed that therapy-related AML has nearly tripled as the cancer survivor population grows — a sobering late-effects story with direct implications for how oncologists counsel patients. Leukemic stem cells were shown to depend on PI3Kα, with EZH1/2 compensation providing a targetable resistance bypass closeable with combination inhibition. CAR-T engineering advances — specifically, forcing cells to express an active Rac1 variant — dramatically improved bone marrow retention and leukemia killing in preclinical models. In lymphoma, a TIM-3 + PD-1 combination achieved 52% response in Hodgkin lymphoma after prior PD-1 failure, and BTK inhibitors are reshaping primary CNS lymphoma first-line treatment.

lung-cancer

Precision and de-escalation shaped lung cancer coverage this week. A PET/CT-guided study identified NSCLC patients who can safely skip radiotherapy after immunotherapy response, while COPD — often seen as a treatment complication — was found to paradoxically boost immunotherapy efficacy through a CXCL14-CXCR4 tumor-macrophage axis that amplifies cytotoxic T cell infiltration. Incidental CT findings emerged as meaningful signals for extrapulmonary cancers, and a nationwide radon atlas in Northern Ireland demonstrated expanded lung screening is warranted in high-radon areas. Mechanistically, BDH2 was identified as a ferroptosis mediator suppressing lung cancer metastasis, and the master transcriptional switch controlling DLL3 — the key target for tarlatamab in SCLC — was identified, opening paths to predict who benefits from DLL3-targeted therapy.

Other Research

This week's broader cancer coverage was anchored by glioblastoma, pancreatic cancer, and a wave of environmental and prevention findings. In GBM, brain support cells were confirmed to fuel tumor growth through paracrine signaling — blocking this communication dramatically slowed tumor growth — while separate work showed that neurosphere cultures from different tumor regions have completely different drug sensitivities, undermining standard single-biopsy drug screening. CA19-9, long used as a pancreatic cancer biomarker, was revealed to actively promote liver metastasis by helping tumor cells adhere to blood vessels. In prevention, residential radon was linked to a 30% higher ovarian cancer risk, and a common cold virus antibody was found to accidentally cross-react with liver cancer cells via molecular mimicry — a finding with vaccine implications. The ADC trastuzumab deruxtecan achieved 70% response rates in HER2-expressing endometrial cancer, while TIL therapy lifileucel showed durable responses with a 36.5-month median duration in metastatic melanoma.

Project Ideas This Week

This week's pipeline generated project ideas spanning diagnostics, patient tools, drug databases, advocacy resources, and clinical decision aids. Recurring themes include microbiome-informed cancer diagnostics, tools for rare KRAS-mutant cancers, patient-facing resources for under-addressed treatment complications, and AI platforms for integrating imaging with molecular data.

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

Feasibility: Medium

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

Feasibility: Medium

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Feasibility: Medium

Cancer Nutrition-Immunity Research Tracker

Zeaxanthin — a carotenoid supplement already taken for eye health — strengthens T cells and enhances immunotherapy effectiveness in preclinical models, suggesting that common dietary compounds may meaningfully modulate cancer immune responses and warrant systematic investigation.

Feasibility: Medium

DCIS Decision Navigator

A randomized trial shows active surveillance for DCIS produces similar ipsilateral invasive breast cancer survival as immediate surgery — a landmark result that means thousands of women per year could potentially avoid surgery, but only if they can access clear information to make an informed…

Feasibility: Medium

Lung Screening Incidental Findings Follow-Up Tracker

Significant incidental findings on lung screening CT are associated with a substantially increased risk of extrapulmonary cancer diagnosis in the following year — meaning lung screening programs are detecting signals for multiple cancer types, but follow-up infrastructure for incidental findings is…

Feasibility: Medium

Prostate Cancer MRI Prognostic Integrator

Pre-treatment MRI features provide independent prognostic information beyond PSA, Gleason grade, and clinical stage in prostate cancer — yet most existing risk calculators don't integrate MRI findings, creating a gap between what imaging tells us and how treatment decisions are made.

Feasibility: Medium

Processed Meat Cancer Warning Label Advocacy Toolkit

The Physicians Committee for Responsible Medicine has petitioned the USDA to add colon cancer warning labels to processed meats — a science-backed public health intervention supported by WHO Group 1 carcinogen designation that lacks a centralized advocacy coordination resource.

Feasibility: High

PostMast: Post-Mastectomy Pain Syndrome Tracker and Community

Post-mastectomy pain syndrome (PMPS) affects a significant subset of mastectomy patients with severe, prolonged neuropathic pain — yet it remains under-recognized, under-treated, and under-studied, partly because patients lack tools to track their symptoms and communicate their experience to…

Feasibility: Medium

Therapy-Related Leukemia Risk Calculator for Cancer Survivors

Therapy-related AML has tripled over 30 years as more cancer survivors live longer after genotoxic chemotherapy and radiation — yet patients and oncologists rarely have accessible tools to quantify this long-term risk when making treatment decisions or planning survivorship surveillance.

Feasibility: Medium

Obesity-Oncology Integrated Care Finder

GLP-1 receptor agonists and bariatric surgery are now proven effective obesity treatments with potential direct anti-cancer effects, but oncology practices and obesity medicine remain siloed — creating a coordination gap for the large fraction of cancer survivors with obesity.

Feasibility: Medium

Colonoscopy Decision Aid for Older Adults

Elderly patients with prior adenomas face very low absolute colorectal cancer risk relative to competing mortality risks — yet surveillance colonoscopy is still widely recommended as routine, even in patients where the procedure's risks and burdens may outweigh realistic cancer prevention benefits.

Feasibility: Medium

Home Radon Cancer Risk Calculator for Women

High residential radon was linked to a 30% higher ovarian cancer risk in postmenopausal women — extending radon's known cancer risk beyond lung cancer and providing new evidence that home radon testing has broader cancer prevention relevance for women.

Feasibility: High

HPV Vaccination Equity Tracker for Males

Large-scale evidence now confirms the 9-valent HPV vaccine cuts cancer risk in males — yet male HPV vaccination rates lag significantly behind female rates in most countries, creating a preventable cancer burden that could be visualized and addressed through data-driven advocacy.

Feasibility: High

CA19-9 Beyond the Biomarker: Patient Education Hub

CA19-9 — the blood test every pancreatic cancer patient gets — is not just a passive indicator of disease; it actively promotes liver metastasis by helping tumor cells stick to liver blood vessels via E-selectin. This mechanistic insight has immediate implications for how patients and clinicians…

Feasibility: High

Lung Cancer Organoid Model Registry

Patient-derived organoids that faithfully recapitulate keratinizing squamous cell carcinoma histology — including spontaneous keratin pearl formation — fill a critical gap in LUSC preclinical modeling, but these rare models are scattered across individual labs with no shared registry.

Feasibility: High

GBM Spatial Heterogeneity Drug Sensitivity Portal

Neurosphere cultures from different regions of the same GBM tumor show completely different drug sensitivities, yet standard drug screening uses single-biopsy cell lines — meaning published drug sensitivity data for GBM may be systematically misleading about what would work in the whole tumor.

Feasibility: Medium

Viral-Cancer Molecular Mimicry Atlas

Common cold virus antibodies accidentally target hepatocellular carcinoma via molecular mimicry with ASPH — revealing that prior viral infection history may create natural cancer protection and that viral epitopes could be engineered into therapeutic cancer vaccines.

Feasibility: Medium

Oncolytic Virus Response Signature Database

RP1 oncolytic virus induces two molecularly distinct CD8+ T cell populations — progenitor-like precursors and terminal effectors — and a precursor-associated gene signature correlates with clinical response to RP1 plus PD-1 blockade in real melanoma patients, making this a candidate predictive…

Feasibility: Medium

PancreAI: Morphology-to-Molecular Subtype Classifier

Four morphological classes of pancreatic cancer (glandular, cribriform, solid, squamous) each have distinct transcriptomic programs and clinical implications — meaning what a pathologist sees under a microscope encodes actionable molecular information that could guide treatment decisions without…

Feasibility: Medium

Rare KRAS-Mutant Cancer Clinical Trial Finder

KRAS inhibitors showed dramatic efficacy in appendiceal adenocarcinoma — a rare cancer with almost no approved treatments — and six real patients with heavily pre-treated disease responded, demonstrating that KRAS-mutant rare cancers outside the mainstream (colon, lung, pancreatic) may be…

Feasibility: High

SCLC DLL3 Biomarker Expression Predictor

POU2F1 acts as the master transcriptional activator of DLL3 in SCLC — meaning DLL3 expression levels, which determine whether patients respond to DLL3-targeted therapies like tarlatamab, are now mechanistically explainable and potentially predictable from upstream transcription factor activity.

Feasibility: Medium

DMG Drug Repurposing Navigator

FDA-approved SSRIs synergize with CDK9 inhibitors to kill diffuse midline glioma cells — meaning drugs that are safe, cheap, brain-penetrant, and already FDA-approved may have immediate translational potential in a childhood brain cancer with no effective treatments.

Feasibility: High

Myelofibrosis Preclinical Model & Target Registry

This study created the first humanized ossicle model that faithfully reproduces myelofibrosis features including reticulin fibrosis and osteosclerosis, and identified SPP1 as a new therapeutic target — highlighting both a model gap and a drug target gap that a structured resource could help address.

Feasibility: Medium

BRCA-Lung Immunotherapy Eligibility Explorer

BRCA1/2 mutations in lung adenocarcinoma predict better responses to immune checkpoint blockade despite worse overall prognosis — creating a paradox that clinicians need tools to navigate when making immunotherapy decisions for NSCLC patients.

Feasibility: High

Pre-Cancer Cell Communication Network Atlas

Transformed breast cells use physical nanotube connections to transmit BMP signaling to normal neighbors, actively spreading a preneoplastic state — meaning early cancer initiation may be a contagious process, not just isolated mutations.

Feasibility: Medium

AML Resistance Pathway Mapper

When PI3K is blocked in AML cells, the cancer compensates by upregulating EZH1 — an escape route that can be closed by combining PI3K inhibitors with EZH1/2 dual inhibitors. This research makes a compelling case for systematically mapping known resistance bypass routes and their combination therapy…

Feasibility: Medium

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

Feasibility: Medium

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

Feasibility: Medium

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Feasibility: Medium

Cancer Nutrition-Immunity Research Tracker

Zeaxanthin — a carotenoid supplement already taken for eye health — strengthens T cells and enhances immunotherapy effectiveness in preclinical models, suggesting that common dietary compounds may meaningfully modulate cancer immune responses and warrant systematic investigation.

Feasibility: Medium

DCIS Decision Navigator

A randomized trial shows active surveillance for DCIS produces similar ipsilateral invasive breast cancer survival as immediate surgery — a landmark result that means thousands of women per year could potentially avoid surgery, but only if they can access clear information to make an informed…

Feasibility: Medium

Lung Screening Incidental Findings Follow-Up Tracker

Significant incidental findings on lung screening CT are associated with a substantially increased risk of extrapulmonary cancer diagnosis in the following year — meaning lung screening programs are detecting signals for multiple cancer types, but follow-up infrastructure for incidental findings is…

Feasibility: Medium

Prostate Cancer MRI Prognostic Integrator

Pre-treatment MRI features provide independent prognostic information beyond PSA, Gleason grade, and clinical stage in prostate cancer — yet most existing risk calculators don't integrate MRI findings, creating a gap between what imaging tells us and how treatment decisions are made.

Feasibility: Medium

Processed Meat Cancer Warning Label Advocacy Toolkit

The Physicians Committee for Responsible Medicine has petitioned the USDA to add colon cancer warning labels to processed meats — a science-backed public health intervention supported by WHO Group 1 carcinogen designation that lacks a centralized advocacy coordination resource.

Feasibility: High

PostMast: Post-Mastectomy Pain Syndrome Tracker and Community

Post-mastectomy pain syndrome (PMPS) affects a significant subset of mastectomy patients with severe, prolonged neuropathic pain — yet it remains under-recognized, under-treated, and under-studied, partly because patients lack tools to track their symptoms and communicate their experience to…

Feasibility: Medium

Therapy-Related Leukemia Risk Calculator for Cancer Survivors

Therapy-related AML has tripled over 30 years as more cancer survivors live longer after genotoxic chemotherapy and radiation — yet patients and oncologists rarely have accessible tools to quantify this long-term risk when making treatment decisions or planning survivorship surveillance.

Feasibility: Medium

Obesity-Oncology Integrated Care Finder

GLP-1 receptor agonists and bariatric surgery are now proven effective obesity treatments with potential direct anti-cancer effects, but oncology practices and obesity medicine remain siloed — creating a coordination gap for the large fraction of cancer survivors with obesity.

Feasibility: Medium

Colonoscopy Decision Aid for Older Adults

Elderly patients with prior adenomas face very low absolute colorectal cancer risk relative to competing mortality risks — yet surveillance colonoscopy is still widely recommended as routine, even in patients where the procedure's risks and burdens may outweigh realistic cancer prevention benefits.

Feasibility: Medium

Home Radon Cancer Risk Calculator for Women

High residential radon was linked to a 30% higher ovarian cancer risk in postmenopausal women — extending radon's known cancer risk beyond lung cancer and providing new evidence that home radon testing has broader cancer prevention relevance for women.

Feasibility: High

HPV Vaccination Equity Tracker for Males

Large-scale evidence now confirms the 9-valent HPV vaccine cuts cancer risk in males — yet male HPV vaccination rates lag significantly behind female rates in most countries, creating a preventable cancer burden that could be visualized and addressed through data-driven advocacy.

Feasibility: High

CA19-9 Beyond the Biomarker: Patient Education Hub

CA19-9 — the blood test every pancreatic cancer patient gets — is not just a passive indicator of disease; it actively promotes liver metastasis by helping tumor cells stick to liver blood vessels via E-selectin. This mechanistic insight has immediate implications for how patients and clinicians…

Feasibility: High

Lung Cancer Organoid Model Registry

Patient-derived organoids that faithfully recapitulate keratinizing squamous cell carcinoma histology — including spontaneous keratin pearl formation — fill a critical gap in LUSC preclinical modeling, but these rare models are scattered across individual labs with no shared registry.

Feasibility: High

GBM Spatial Heterogeneity Drug Sensitivity Portal

Neurosphere cultures from different regions of the same GBM tumor show completely different drug sensitivities, yet standard drug screening uses single-biopsy cell lines — meaning published drug sensitivity data for GBM may be systematically misleading about what would work in the whole tumor.

Feasibility: Medium

Viral-Cancer Molecular Mimicry Atlas

Common cold virus antibodies accidentally target hepatocellular carcinoma via molecular mimicry with ASPH — revealing that prior viral infection history may create natural cancer protection and that viral epitopes could be engineered into therapeutic cancer vaccines.

Feasibility: Medium

Oncolytic Virus Response Signature Database

RP1 oncolytic virus induces two molecularly distinct CD8+ T cell populations — progenitor-like precursors and terminal effectors — and a precursor-associated gene signature correlates with clinical response to RP1 plus PD-1 blockade in real melanoma patients, making this a candidate predictive…

Feasibility: Medium

PancreAI: Morphology-to-Molecular Subtype Classifier

Four morphological classes of pancreatic cancer (glandular, cribriform, solid, squamous) each have distinct transcriptomic programs and clinical implications — meaning what a pathologist sees under a microscope encodes actionable molecular information that could guide treatment decisions without…

Feasibility: Medium

Rare KRAS-Mutant Cancer Clinical Trial Finder

KRAS inhibitors showed dramatic efficacy in appendiceal adenocarcinoma — a rare cancer with almost no approved treatments — and six real patients with heavily pre-treated disease responded, demonstrating that KRAS-mutant rare cancers outside the mainstream (colon, lung, pancreatic) may be…

Feasibility: High

SCLC DLL3 Biomarker Expression Predictor

POU2F1 acts as the master transcriptional activator of DLL3 in SCLC — meaning DLL3 expression levels, which determine whether patients respond to DLL3-targeted therapies like tarlatamab, are now mechanistically explainable and potentially predictable from upstream transcription factor activity.

Feasibility: Medium

DMG Drug Repurposing Navigator

FDA-approved SSRIs synergize with CDK9 inhibitors to kill diffuse midline glioma cells — meaning drugs that are safe, cheap, brain-penetrant, and already FDA-approved may have immediate translational potential in a childhood brain cancer with no effective treatments.

Feasibility: High

Myelofibrosis Preclinical Model & Target Registry

This study created the first humanized ossicle model that faithfully reproduces myelofibrosis features including reticulin fibrosis and osteosclerosis, and identified SPP1 as a new therapeutic target — highlighting both a model gap and a drug target gap that a structured resource could help address.

Feasibility: Medium

BRCA-Lung Immunotherapy Eligibility Explorer

BRCA1/2 mutations in lung adenocarcinoma predict better responses to immune checkpoint blockade despite worse overall prognosis — creating a paradox that clinicians need tools to navigate when making immunotherapy decisions for NSCLC patients.

Feasibility: High

Pre-Cancer Cell Communication Network Atlas

Transformed breast cells use physical nanotube connections to transmit BMP signaling to normal neighbors, actively spreading a preneoplastic state — meaning early cancer initiation may be a contagious process, not just isolated mutations.

Feasibility: Medium

AML Resistance Pathway Mapper

When PI3K is blocked in AML cells, the cancer compensates by upregulating EZH1 — an escape route that can be closed by combining PI3K inhibitors with EZH1/2 dual inhibitors. This research makes a compelling case for systematically mapping known resistance bypass routes and their combination therapy…

Feasibility: Medium

Read more